title: Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.
abstract: Cross-trial comparisons are typically inappropriate as there are often numerous differences in study designs, populations, end points, and loading doses of the study drugs. These differences are clearly reflected in the most recent updates to the European Society of Cardiology (ESC) non-ST elevation acute coronary syndrome (NSTE-ACS) and ST elevation myocardial infarction (STEMI) guidelines, which include recommendations for the use of the antiplatelet agents ticagrelor, prasugrel, and clopidogrel, based in part on results from the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel-Thrombolysis In Myocardial Infarction (TRITON-TIMI) 38, TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY-ACS) and PLATelet inhibition and patient Outcomes (PLATO) trials. Here, we describe each of these trials in detail and explain the differences between them that make direct comparisons difficult. In conclusion, this information, along with the current guidelines and recommendations, will assist clinicians in deciding the most appropriate treatment pathway for their patients with NSTE-ACS and STEMI.
authors.affiliation: 1Department of Medicine, Hospital Unit West, Herning, Denmark; and 2Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Steen
authors.initials: S
authors.lastname: Husted
authors.forename: Eric
authors.initials: E
authors.lastname: Boersma
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077144:Clopidogrel; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy*; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine
references.citation: Am Heart J. 2009 Apr;157(4):599-605
references.pmid: 19332184
references.citation: Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):680-8
references.pmid: 22991347
references.citation: Lancet. 2009 Feb 28;373(9665):723-31
references.pmid: 19249633
references.citation: N Engl J Med. 2013 Sep 12;369(11):999-1010
references.pmid: 23991622
references.citation: N Engl J Med. 2009 Sep 10;361(11):1045-57
references.pmid: 19717846
references.citation: N Engl J Med. 2012 Oct 4;367(14):1297-309
references.pmid: 22920930
references.citation: N Engl J Med. 2014 Sep 11;371(11):1016-27
references.pmid: 25175921
references.citation: Eur Heart J. 2013 Jun;34(23):1708-13, 1713a-1713b
references.pmid: 23425521
references.citation: Cardiovasc Revasc Med. 2011 Mar-Apr;12(2):94-8
references.pmid: 21421187
references.citation: Am J Cardiol. 2011 Oct 1;108(7):905-11
references.pmid: 21816379
references.citation: Eur Heart J. 2002 Aug;23(15):1177-89
references.pmid: 12127920
references.citation: Lancet. 2009 Sep 19;374(9694):989-997
references.pmid: 19726078
references.citation: Lancet. 2013 Aug 17;382(9892):605-13
references.pmid: 23953385
references.citation: Catheter Cardiovasc Interv. 2012 Feb 15;79(3):453-95
references.pmid: 22328235
references.citation: Circulation. 2012 Feb 28;125(8):978-86
references.pmid: 22261200
references.citation: Int J Cardiol. 2011 Aug 4;150(3):325-31
references.pmid: 20828843
references.citation: Eur Heart J. 2012 Oct;33(20):2569-619
references.pmid: 22922416
references.citation: Chest. 2008 Jun;133(6 Suppl):708S-775S
references.pmid: 18574277
references.citation: Int J Cardiol. 2012 Oct 18;160(3):171-4
references.pmid: 21543126
references.citation: Circulation. 2010 Nov 23;122(21):2131-41
references.pmid: 21060072
references.citation: J Am Coll Cardiol. 2006 Jul 4;48(1):193-202
references.pmid: 16814667
references.citation: J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140
references.pmid: 23256914
references.citation: Chest. 2012 Feb;141(2 Suppl):e637S-e668S
references.pmid: 22315274
references.citation: Eur Heart J. 2010 Dec;31(24):3006-16
references.pmid: 20802246
references.citation: Am Heart J. 2006 Oct;152(4):627-35
references.pmid: 16996826
references.citation: Am J Cardiol. 2011 Dec 1;108(11):1542-6
references.pmid: 21890085
references.citation: N Engl J Med. 2007 Nov 15;357(20):2001-15
references.pmid: 17982182
references.citation: Lancet. 2012 Apr 14;379(9824):1393-402
references.pmid: 22445239
references.citation: Eur Heart J. 2011 Dec;32(23):2933-44
references.pmid: 22090660
references.citation: Eur Heart J. 2011 Dec;32(23):2999-3054
references.pmid: 21873419
references.citation: Circulation. 2009 Jun 2;119(21):2758-64
references.pmid: 19451347
references.citation: Circulation. 2014 Dec 23;130(25):e344-426
references.pmid: 25249585
references.citation: Eur Heart J. 2014 Oct 1;35(37):2541-619
references.pmid: 25173339
references.citation: Circulation. 2012 Jun 12;125(23):2914-21
references.pmid: 22572911
references.citation: Circulation. 2009 Dec 22;120(25):2577-85
references.pmid: 19923168
references.citation: J Am Coll Cardiol. 2011 May 10;57(19):1908-16
references.pmid: 21545948
references.citation: J Am Coll Cardiol. 2014 Apr 22;63(15):1493-9
references.pmid: 24561148
references.citation: Am Heart J. 2010 Jul;160(1):16-22.e1
references.pmid: 20598967
references.citation: Circulation. 2008 Oct 14;118(16):1626-36
references.pmid: 18757948
references.citation: Circulation. 2013 Aug 20;128(8):823-33
references.pmid: 23852610